Bayer (FRA:BAYN) Given a €77.00 Price Target by Goldman Sachs Group Analysts

Goldman Sachs Group set a €77.00 ($89.53) price objective on Bayer (FRA:BAYN) in a research report sent to investors on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Several other brokerages have also weighed in on BAYN. Warburg Research set a €17.00 ($19.77) target price on shares of Leoni and gave the company a neutral rating in a research report on Wednesday, May 15th. Kepler Capital Markets set a €70.00 ($81.40) target price on shares of Bayer and gave the company a neutral rating in a research report on Thursday, June 27th. DZ Bank upgraded shares of Telefonica from a hold rating to a buy rating in a research report on Tuesday, May 14th. Credit Suisse Group set a $43.00 target price on shares of SEA and gave the company a buy rating in a research report on Thursday, July 4th. Finally, Nord/LB reiterated a neutral rating on shares of Bayerische Motoren Werke in a research report on Tuesday, June 4th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the company. Bayer has a consensus rating of Hold and a consensus price target of €80.67 ($93.81).

Shares of Bayer stock opened at €59.96 ($69.72) on Monday. The company’s 50-day simple moving average is €56.55. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: What is a dead cat bounce?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.